ZBIOZBIOHealthcare · Biotechnology

ZBIO Stock Forecast: Zenas BioPharma, Inc. Price Predictions for 2026-2027

Last close, 16 Nov 2026
$28
−0.29% on the day

The 8 Wall Street analysts covering Zenas BioPharma, Inc. hold a median 12-month price target of $47 — +66.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 14 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
21/ 100
Median analyst target
$47
Analysts covering
8
Revenue$1.0M
Operating income−$77.7M
Net income−$111.5M
Free cash flow−$87.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.2%
1M
+12.4%
YTD
−23.1%
1Y
−20.2%
From 52W high
−35.3%
From 52W low
+83.8%
$15
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zenas BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Nov 2026
21/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
66
Volatility
59
Value
59
Accruals
43
Size
35
Revisions
34
Quality
32
Growth
24
Issuance
5

Momentum (66): The shares have been drifting up relative to others.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ZBIOHigh $59Median $47Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $32Median $47High $59

The green dot is the last close — the median target sits +66.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026HC Wainwright & Co.ReiteratesBuy$44
30 Sept 2026CitigroupMaintainsBuy—
30 Sept 2026CitigroupMaintainsBuy$41 → $48
30 Sept 2026HC Wainwright & Co.ReiteratesBuy—
30 Sept 2026HC Wainwright & Co.ReiteratesBuy$44
30 Sept 2026WedbushReiteratesOutperform$45
30 Sept 2026WedbushReiteratesOutperform—
14 Aug 2026GuggenheimReiteratesBuy—
14 Aug 2026GuggenheimReiteratesBuy$55
14 Aug 2026Morgan StanleyMaintainsEqual-Weight$22 → $32
14 Aug 2026Morgan StanleyMaintainsEqual-Weight—
14 Aug 2026WedbushReiteratesOutperform$45
14 Aug 2026WedbushReiteratesOutperform—
15 May 2026HC Wainwright & Co.ReiteratesBuy$44
15 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026Morgan StanleyMaintainsEqual-Weight—
14 May 2026Morgan StanleyMaintainsEqual-Weight$21 → $22
17 Mar 2026CitigroupMaintainsBuy—
17 Mar 2026GuggenheimMaintainsBuy—
17 Mar 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ZBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ZBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 16 Nov 2026, Zenas BioPharma, Inc. returned −20.2% against +13.5% for the S&P 500, dividends included.

ZBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ZBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Zenas BioPharma, Inc. (ZBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.6×

Cheaper than 70% of US stocks

Price / sales
172.2×

Cheaper than 3% of US stocks

Price / book
8.9×

Cheaper than 10% of US stocks

EV / EBITDA
−5.3×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−2747.5%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−265.1%

Higher than 5% of US stocks

Return on assets
−37.9%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 63% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zenas BioPharma, Inc. (ZBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zenas BioPharma, Inc. has a market value of $1.9B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $1.0M.

  • Net income over the same four quarters: −$484.4M, a −48438.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$8.99.

  • Free cash flow in the twelve months to 30 June 2026: −$291.0M.

  • Shares outstanding: 63.3M.

  • Trailing P/E: 1.6×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.03%, paying out 0% of earnings.

  • Zenas BioPharma, Inc. employs 167 people — $6K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Nov 2026

Data provided by Twelve Data

Peers

ZBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZBIOZenas BioPharma, Inc.$1.9B21
MAZEMaze Therapeutics, Inc.$1.9B25
RXRXRecursion Pharmaceuticals, Inc.$1.9B59
COAGHemab Therapeutics Holdings, Inc.$1.9B1
AGIOAgios Pharmaceuticals, Inc.$1.9B83
FTREFortrea Holdings, Inc.$1.9B93
ZYMEZymeworks, Inc.$1.9B83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zenas BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZBIO news & analysis

Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 5 Nov 2026positive

Zenas BioPharma reported third-quarter 2026 results and provided a corporate update, including FDA acceptance of its obexelimab BLA for IgG4-RD with a May 27, 2027 PDUFA target date, and submission of an obexelimab MAA to the EMA. The company also reported ongoing clinical programs, upcoming data milestones, and $647.1 million in cash, cash equivalents and investments as of September 30, 2026.

Why it matters — The update outlines regulatory progress for obexelimab, timelines for several clinical readouts, and the company’s reported financial resources.

Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears

MarketBeat · 30 Oct 2026neutral

Zenas BioPharma outlined development plans for obexelimab in systemic lupus erythematosus and for investigational oral IL-17AA/AF inhibitor ZB021 at an R&D event. Clinical data are expected later in the quarter.

Why it matters — The update gives ZBIO watchers information on the company’s plans for two programs and the timing of anticipated clinical data.

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know

Zacks Investment Research · 23 Oct 2026positive

Zacks Investment Research reports that analysts’ mean price target for Zenas BioPharma implies a 77.6% upside. The excerpt cautions that this metric has not proven reasonably effective, while noting that agreement on raising earnings estimates may indicate upside.

Why it matters — ZBIO watchers may note the analysts’ price-target estimate alongside the stated caveat about its reliability and the reported earnings-estimate agreement.

FAQ

Frequently asked questions about ZBIO stock

What is the ZBIO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Zenas BioPharma, Inc. have a median 12-month price target of $47, with estimates ranging from $32 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZBIO stock a buy right now?

Of the 8 analysts covering Zenas BioPharma, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zenas BioPharma, Inc. 21 out of 100 across roughly 4,600 US stocks as at 14 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZBIO?

As at 14 Nov 2026, Zenas BioPharma, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (66 of 100).

Will ZBIO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +66.5% from the last close, and Ticker Nerd's factor model ranks Zenas BioPharma, Inc. 21 out of 100 as at 14 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZBIO stock forecast for 2030?

No analyst covering Zenas BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $59 over the next 12 months.

How has ZBIO stock performed over the past year?

Zenas BioPharma, Inc. returned -20.2% over the 12 months to 16 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zenas BioPharma, Inc. do?

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases.

What is the latest news on ZBIO?

The most recent item we track (GlobeNewsWire, 9 Nov 2026): "Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference". Zenas BioPharma announced that management will present at the Jefferies London Global Healthcare Conference on November 16, 2026, at 5:00 p.m.

Company

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company’s lead program is obexelimab, a bifunctional monoclonal antibody being studied across multiple immune-mediated conditions, including IgG4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Zenas BioPharma also advances a broader pipeline of antibody-based and targeted therapies aimed at modulating immune pathways involved in chronic autoimmune disorders. Based in Waltham, Massachusetts, the company operates as a research-driven drug developer with current activities centered on clinical development, regulatory progress, and building a portfolio of therapies for patients with significant unmet medical needs.

CEO Mr. Leon Oliver Moulder Jr., M.B.A. · 167 employees · United States · https://zenasbio.com